120 related articles for article (PubMed ID: 7524706)
1. Identification of epitopes and affinity purification of thyroid stimulating auto-antibodies using synthetic human TSH receptor peptides.
Morris JC; Gibson JL; Haas EJ; Bergert ER; Dallas JS; Prabhakar BS
Autoimmunity; 1994; 17(4):287-99. PubMed ID: 7524706
[TBL] [Abstract][Full Text] [Related]
2. Identification of thyroid blocking antibodies and receptor epitopes in autoimmune hypothyroidism by affinity purification using synthetic TSH receptor peptides.
Bryant WP; Bergert ER; Morris JC
Autoimmunity; 1995; 22(2):69-79. PubMed ID: 8722576
[TBL] [Abstract][Full Text] [Related]
3. Presence of heterogeneous thyroid-stimulating antibodies in sera from individual Graves' patients as shown by synthesized thyrotropin receptor peptide application: evidence showing two independent epitopes and a possible recognition of two epitopic regions by one antibody molecule.
Sugawa H; Akamizu T; Kosugi S; Ueda Y; Ohta C; Okuda J; Mori T
Eur J Endocrinol; 1995 Sep; 133(3):283-93. PubMed ID: 7581943
[TBL] [Abstract][Full Text] [Related]
4. Graves' immunoglobulins activate phospholipase A2 by recognizing specific epitopes on thyrotropin receptor.
Di Cerbo A; Di Paola R; Menzaghi C; De Filippis V; Tahara K; Corda D; Kohn LD
J Clin Endocrinol Metab; 1999 Sep; 84(9):3283-92. PubMed ID: 10487700
[TBL] [Abstract][Full Text] [Related]
5. Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody.
Ochi Y; Kajita Y; Hamazu M; Nagata A
Horm Res; 2003; 59(5):222-8. PubMed ID: 12714785
[TBL] [Abstract][Full Text] [Related]
6. Thyroid-stimulating antibodies in sera from patients with Graves' disease are heterogeneous in epitope recognition.
Ueda Y; Sugawa H; Akamizu T; Okuda J; Ueda M; Kosugi S; Ohta C; Kihou Y; Mori T
Eur J Endocrinol; 1995 Jan; 132(1):62-8. PubMed ID: 7531576
[TBL] [Abstract][Full Text] [Related]
7. Affinity-enrichment of thyrotropin receptor autoantibodies from Graves' patients and normal individuals provides insight into their properties and possible origin from natural antibodies.
Latrofa F; Chazenbalk GD; Pichurin P; Chen CR; McLachlan SM; Rapoport B
J Clin Endocrinol Metab; 2004 Sep; 89(9):4734-45. PubMed ID: 15356088
[TBL] [Abstract][Full Text] [Related]
8. Characterization of recombinant monoclonal antithyrotropin receptor antibodies (TSHRAbs) derived from lymphocytes of patients with Graves' disease: epitope and binding study of two stimulatory TSHRAbs.
Akamizu T; Moriyama K; Miura M; Saijo M; Matsuda F; Nakao K
Endocrinology; 1999 Apr; 140(4):1594-601. PubMed ID: 10098493
[TBL] [Abstract][Full Text] [Related]
9. Detection of functionally different types of pathological autoantibodies against thyrotropin receptor in Graves' patients sera by luminescent immunoprecipitation analysis.
Minich WB; Loos U
Exp Clin Endocrinol Diabetes; 2000; 108(2):110-9. PubMed ID: 10826518
[TBL] [Abstract][Full Text] [Related]
10. T-cells recognize multiple epitopes in the human thyrotropin receptor extracellular domain.
Soliman M; Kaplan E; Yanagawa T; Hidaka Y; Fisfalen ME; DeGroot LJ
J Clin Endocrinol Metab; 1995 Mar; 80(3):905-14. PubMed ID: 7533773
[TBL] [Abstract][Full Text] [Related]
11. Identification of the peptides that inhibit the stimulation of thyrotropin receptor by Graves' immunoglobulin G from peptide libraries.
Park JY; Kim IJ; Lee MH; Seo JK; Suh PG; Cho BY; Ryu SH; Chae CB
Endocrinology; 1997 Feb; 138(2):617-26. PubMed ID: 9002995
[TBL] [Abstract][Full Text] [Related]
12. The extracellular domain of the TSH receptor has an immunogenic epitope reactive with Graves' IgG but unrelated to receptor function as well as determinants having different roles for high affinity TSH binding and the activity of thyroid-stimulating autoantibodies.
Kosugi S; Akamizu T; Takai O; Prabhakar BS; Kohn LD
Thyroid; 1991; 1(4):321-30. PubMed ID: 1726785
[TBL] [Abstract][Full Text] [Related]
13. Identification of the peptides that inhibit the function of human monoclonal thyroid-stimulating antibodies from phage-displayed peptide library.
Byun CH; Park JY; Akamizu T; Chae CB
J Clin Endocrinol Metab; 2001 Jul; 86(7):3311-8. PubMed ID: 11443206
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity in cellular and antibody responses against thyrotropin receptor in patients with Graves' disease detected using synthetic peptides.
Fan JL; Desai RK; Seetharamaiah GS; Dallas JS; Wagle NM; Prabhakar BS
J Autoimmun; 1993 Dec; 6(6):799-808. PubMed ID: 7512341
[TBL] [Abstract][Full Text] [Related]
15. A method for identification of the peptides that bind to a clone of thyroid-stimulating antibodies in the serum of Graves' disease patients.
Na CH; Lee MH; Cho BY; Chae CB
J Clin Endocrinol Metab; 2003 Apr; 88(4):1570-6. PubMed ID: 12679441
[TBL] [Abstract][Full Text] [Related]
16. Thyrotropin (TSH) receptor antibodies (TSHrAb) can inhibit TSH-mediated cyclic adenosine 3',5'- monophosphate production in thyroid cells by either blocking TSH binding or affecting a step subsequent to TSH binding.
Dallas JS; Cunningham SJ; Patibandla SA; Seetharamaiah GS; Morris JC; Tahara K; Kohn LD; Prabhakar BS
Endocrinology; 1996 Aug; 137(8):3329-39. PubMed ID: 8754759
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of thyroid-stimulating and -blocking antibodies to the thyrotropin receptor in a murine model of Graves' disease.
Muehlberg T; Gilbert JA; Rao PV; McGregor AM; Banga JP
Endocrinology; 2004 Apr; 145(4):1539-45. PubMed ID: 14764633
[TBL] [Abstract][Full Text] [Related]
18. Epitopes for thyroid-stimulating antibodies in Graves' sera: a possible link of heterogeneity to differences in response to antithyroid drug treatment.
Kim WB; Cho BY; Park HY; Lee HK; Kohn LD; Tahara K; Koh CS
J Clin Endocrinol Metab; 1996 May; 81(5):1758-67. PubMed ID: 8626830
[TBL] [Abstract][Full Text] [Related]
19. Human thyrotropin receptor subunits characterized by thyrotropin affinity purification and western blotting.
Leedman PJ; Newman JD; Harrison LC
J Clin Endocrinol Metab; 1989 Jul; 69(1):134-41. PubMed ID: 2471709
[TBL] [Abstract][Full Text] [Related]
20. Analysis of autoantibody reactivity in patients with Graves' disease using recombinant extracellular domain of the human thyrotropin receptor and synthetic peptides.
Fan JL; Seetharamaiah GS; Desai RK; Dallas JS; Wagle NM; Prabhakar BS
Autoimmunity; 1993; 15(4):285-91. PubMed ID: 8136456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
